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• Current osteoporosis therapies can reduce the risk of fractures and thus costs, but adherence to these medications is often poor
• Osteoporosis is a high prevalence and high cost bone disorder. • The model calculated total fracture-related costs for all patients in 2010 at €4.4 billion (with 69.6% for direct medical costs, 20.2% for long-term nursing care, and 10.2% for work loss) (cumulative: Figure 2) • For the estimated 4.2% of treated patients, the model calculated total fracture-related costs at €184.9 million
• Fracture-related cost savings totalled €27.8 million for 2010 alone (cumulative: Figure 3) Cost: Total and Avoided by Fracture Type
• Increasing the % of patients with effective adherence from 54% to 100% decreased costs for hip (16.2%), vertebral (24.4%) and NHNV fractures (6.3%) (Figure 3) • Primary Objective: To estimate yearly potential savings in fracture-related costs from improved adherence to osteoporosis therapies in Germany from a societal perspective
• Secondary Objective: To create a flexible modelling tool to demonstrate the value of improved adherence to managers of health plans
• Only this model allows users to manipulate all factors in the relationship between medication adherence and cost outcomes in real time
• Only a small portion of the population was treated. Greater adherence improved savings significantly but the total saved was small compared to total costs of osteoporotic fractures in the untreated population
• Although the model used up-to-date estimates, there was lack of consistency in the literature on definitions of adherehnce and costs of fractures. There will be uncertainty in estimated cost savings for treating osteoporosis until these problems are solved
• The model is limited by empirical estimates. In particular, precise data on treatment and adherence in older populations are lacking. The highest proportion of costly fractures occurred among elderly women and model accuracy would be vastly improved with more precise statistics. The variation in cost estimates was also unreasonably high. Better measurement of costs along with patient characteristics would improve the precision of osteoporosis cost estimates and the value of treatments for reducing fractures
• Savings from improved adherence can be modelled in a flexible, transparent multivariate, real-world, real-time environment
• Applying the described model to the German population suggests that achieving full adherence to medication among women currently treated for osteoporosis in Germany would reduce fractures and cut down annual fracture-related costs by €27.8 million (15.1%) Base Inputs (see Table 1 Removing HRT reduced the proportion treated to 4.2%. This is similar to estimates reported for other countries 2 • Medications: Based on industry estimates: oral bisphosphonates (94.6%), strontium (2.7%), raloxifene (2.6%), assumed equal for each age cohort. Medication costs were not considered
• Adherence:
-MPR for 1-year periods. Effective adherence (MPR > 50%) estimated at 54% for each medication class based on the GRAND study, were used to estimate vertebral and NHNV fracture incidence from German hip fracture incidence data
Base Inputs (continued)
• Costs for Health Care Resource Use (the direct costs of treating fractures, including hospitalizations, physical therapy, etc.); Work Loss (wages paid to workers for days of work missed due to fractures); and Lost Functionality (costs for nursing home care or home health care) were drawn from studies by Konnopka et al, 12 and from reports published by the Health Reporting of the Federation: General Local Health Insurance Funds.
13
The Borgstrom et al 11 research was used to estimate the costs of vertebral fractures and was based on Swedish data, which is assumed to give a reasonable approximation of German costs
Analyses Performed
• Fracture Cost Savings Due to Improved Adherence: We estimated current costs with 54% effectively adherent and 100% effectively adherent, for the base year (2010) and for each year out to 2014. Savings due to improved adherence were calculated for each category of costs
• Sensitivity Analysis: Two one-way sensitivity analyses were conducted, one for total population and the second for treated population, over seven factors. The model was most sensitive to variations in direct costs per fracture. We also ran a two-way sensitivity analysis that looked at the interaction between increased % treated and improved adherence
Structure
The model ( Figure 1 ) was a deterministic cohort model developed in Microsoft Excel. Parameters can be changed to determine independent or combined effects on outcomes 
